Meeting
2022 ASCO Annual Meeting
Multiomics profiling and association with molecular and immune features in association with benefits from immunotherapy for patients with previously treated stage IV or recurrent squamous cell lung cancer from the phase III SWOG LungMAP S1400I trial.
Authors
Edwin R. Parra
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX
Edwin R. Parra , Dzifa Yawa Duose , Jiexin Zhang , Mary Weber Redman , Rossana Lazcano Segura , Mario L. Marques-Piubelli , Caddie Laberiano Fernandez , BaiLi Zhang , James Lindsay , Radim Moravec , Kasthuri Kannan , Rajyalakshmi Luthra , Gheath Alatrash , Roy S. Herbst , Ignacio Ivan Wistuba , Scott N. Gettinger , Lyudmila Bazhenova , J. Jack Lee , Jianjun Zhang , Cara L. Haymaker
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9046)
DOI
10.1200/JCO.2022.40.16_suppl.9046
Abstract #
9046
Poster Bd #
34
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A pilot study of ipilimumab and nivolumab in recurrent extensive-stage small cell lung cancer after platinum-based chemotherapy.
First Author: Anne C. Chiang
Poster
2021 ASCO Annual Meeting
Examination of the tumor immune microenvironment (TIME) with multispectral immunofluorescence (m-IF): Association of markers with prognosis and bevacizumab (bev) benefit in NRG Oncology/NSABP C-08.
First Author: Katherine L. Pogue-Geile
Poster
2019 ASCO Annual Meeting
A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952).
First Author: Lyudmila Bazhenova
Poster
2016 ASCO Annual Meeting
Immunologic profiling of consensus molecular subtype (CMS) stratified colorectal cancer (CRC) primary and liver metastectomy specimens: Implications for immune targeting of proficient mismatch repair CRC.
First Author: Matthew Reilley